BLRX · BioLineRx Ltd.
Market Cap
$12.23M
Shares
4.37M
BLRX metrics
30 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$2.76
Market cap
$12.23M
Price action
19 metricsPrice change (1W)
-3.2%
Price change (30D)
+3.8%
Price change (3M)
-18.6%
Price change (6M)
-1.8%
Price change (YTD)
-0.4%
Price change (1Y)
-27.2%
Trailing year
Price change (5Y)
—
52-week high
$4.44
52-week low
$2.18
Change from 52-week high
-37.8%
Change from 52-week low
+26.6%
Annualized volatility
62.8%
Beta
0.6
RSI (14D)
48.4
Price vs SMA 50
-4.8%
Price vs SMA 200
-5.2%
Avg volume (3M)
19,938
Relative volume
3.5
Average dollar volume
$59,401
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
4.37M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-09-30
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
14
13F filer change QoQ
0
Institutional ownership
2.4%
Short interest
3 metricsShort interest
3.1%
Latest settlement · 19.8 days to cover
Days to cover
19.8d
Short-squeeze score
57 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1498403
CUSIP
09071M304
13F (30d)
12 filings
12 filers
Visit website
Investor relations